10x Genomics, Inc.

10x Genomics, Inc.

TXG

$75.62

Updated: 23/09/2026, 23:33:19

Market Cap
$9.60B
Sector
Healthcare
Industry
Biotechnology
Country
US
Stock valuation chart
One-year closing share-price history for TXG
Company Profile

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

USD
NASDAQ
CEO: Serge Saxonov
Employees: 1,178
https://www.10xgenomics.com
Asset Summaries
Latest generated summaries for TXG

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for TXG.
Share price
$75.62
Market cap
$9.60B
Exchange
NASDAQ
Currency
USD
CEO
Serge Saxonov
Employees
1,178
IPO date
12/09/2019
Beta
2.077
Last dividend
$0.00
Day range
$74.75 – $81.93
52-week range
$11.16 – $82.68
1-day performance
-6.29%
1-year performance
577.60%
Current drawdown (1Y)
-8.54%
CIK
0001770787
CUSIP
88025U109
ISIN
US88025U1097
Created
07/12/2025, 14:50:39
Last update
23/09/2026, 23:33:19

Track 10x Genomics, Inc. with an AI analyst

See which prediction-market events move TXG, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to TXG from your Railway `news_articles` table.